Loading
FN1 (Fibronectin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonisation, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralisation.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming L19IL2, Dacarbazine and Daromun. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 1.00, affected pathway 0.98, genetic association 0.03, clinical 0.19).
In plain words · FN1 (Fibronectin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
FN1 (Fibronectin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonisation, wound healing, and maintenance of cell shape.
No product in this corpus aims at FN1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FN1: RNA tissue enhanced (blood vessel 2,746 nTPM, liver 1,614 nTPM, placenta 2,752 nTPM); high antibody staining in 4 normal tissues; highest cancer staining pancreatic cancer (3 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas FN1 tissue; Open Targets ENSG00000115414 associations
First described 1982. Earliest sequence paper UniProt cites for the protein: Pierschbacher M.D. et al, J. Biol. Chem, 1982, "The cell attachment domain of fibronectin. Determination of the primary structure". Source.
Sources: HGNC HGNC:3778 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P02751 (protein name, function text, keywords and locations (REST API)); CIViC gene FN1 (3 evidence items, 0 assertions, 1 variants; diseases: Melanoma (GraphQL API, CC0)); Open Targets ENSG00000115414 (association with cancer (MONDO_0004992) 0.64; (GraphQL API, CC0))
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonisation, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralisation. Participates in the regulation of type I collagen deposition by osteoblasts. Acts as a ligand for the LILRB4 receptor, inhibiting FCGR1A/CD64-mediated monocyte activation. Binds fibronectin and induces fibril formation. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 2q35 (HGNC).
RNA: tissue enhanced (blood vessel 2,746 nTPM, liver 1,614 nTPM, placenta 2,752 nTPM), detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Cerebellum, Cerebral cortex, Colon, Duodenum, Gallbladder, Heart muscle.
RNA cancer enhanced: Thyroid Carcinoma 3,347 pTPM.
Medium only: breast cancer, lung cancer, melanoma, skin cancer.
HPA FN1 tissue · HPA FN1 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FN1" OR ABSTRACT:"FN1" OR TITLE:"fibronectin 1" OR ABSTRACT:"fibronectin 1" OR TITLE:"Fibronectin" OR ABSTRACT:"Fibronectin" OR TITLE:"GFND2" OR ABSTRACT:"GFND2" OR TITLE:"lnc-ABCA12-8" OR ABSTRACT:"lnc-ABCA12-8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FN1, not a curated reading list.